Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
New roads open up for implementing immunotherapy in mesothelioma.
Cornelissen R, Heuvers ME, Maat AP, Hendriks RW, Hoogsteden HC, Aerts JG, Hegmans JP. Cornelissen R, et al. Among authors: aerts jg. Clin Dev Immunol. 2012;2012:927240. doi: 10.1155/2012/927240. Epub 2012 Jun 24. Clin Dev Immunol. 2012. PMID: 22778767 Free PMC article. Review.
Dendritic cell-based immunotherapy in mesothelioma.
Cornelissen R, Lievense LA, Heuvers ME, Maat AP, Hendriks RW, Hoogsteden HC, Hegmans JP, Aerts JG. Cornelissen R, et al. Immunotherapy. 2012 Oct;4(10):1011-22. doi: 10.2217/imt.12.108. Immunotherapy. 2012. PMID: 23148753 Review.
Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).
Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ. Barlesi F, et al. Among authors: aerts jg. J Clin Oncol. 2013 Aug 20;31(24):3004-11. doi: 10.1200/JCO.2012.42.3749. Epub 2013 Jul 8. J Clin Oncol. 2013. PMID: 23835708 Clinical Trial.
Reply to B.M. Strebel.
Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Kim JH, Ahn MJ, Aerts JG, Vikström A, Groen HJ. Barlesi F, et al. Among authors: aerts jg. J Clin Oncol. 2014 Feb 10;32(5):479-80. doi: 10.1200/JCO.2013.53.7175. Epub 2013 Dec 30. J Clin Oncol. 2014. PMID: 24378413 No abstract available.
Biomarkers for immune checkpoint inhibitors.
Lievense LA, Hegmans JP, Aerts JG. Lievense LA, et al. Among authors: aerts jg. Lancet Oncol. 2014 Jan;15(1):e1. doi: 10.1016/S1470-2045(13)70557-6. Lancet Oncol. 2014. PMID: 24384488 No abstract available.
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators. Soria JC, et al. Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5. Lancet Oncol. 2015. PMID: 26156651 Clinical Trial.
1,173 results